WeVote

Bill

Bill

HB 943

Establish the Montana rare disease advisory council

2025 Regular Session Introduced by Paul Tuss

Montana establishes rare disease advisory council to coordinate state resources, research guidance, and patient support policies for citizens with rare medical conditions.

Chapter Number Assigned
0
WeVote Research Nonpartisan
Bill Summary · HB 943

Legislative bill overview

HB 943 establishes a Montana rare disease advisory council tasked with providing guidance on policies, research, and patient support related to rare diseases. The council would coordinate among state agencies, healthcare providers, and patient advocacy groups to develop recommendations for improving diagnosis, treatment, and quality of life for Montanans with rare diseases.

Why is this important

Rare diseases affect millions of Americans but receive limited research funding and clinical attention due to small patient populations. Montana residents with rare diseases often face diagnostic delays, limited treatment options, and isolation. Creating an advisory council could help coordinate resources, improve awareness among healthcare providers, and ensure state policies address the unique challenges of rare disease patients.

Potential points of contention

  • Cost and resource allocation: Critics may question whether establishing another advisory council represents an efficient use of state resources during budget constraints, or whether existing health department structures could serve this function
  • Council authority and enforceability: The extent of the council's actual power to influence policy and funding decisions versus serving as an advisory body with limited implementation capacity
  • Scope and definitions: Disagreement over which conditions qualify as "rare diseases" and whether the council's focus could effectively address the extremely diverse medical needs across hundreds of rare conditions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.